Background: Despite recent advances in diagnosis and treatment, tuberculosis (TB) remains a major infectious disease killer in resource-poor settings. Strategies to prevent Mycobacterium tuberculosis (Mtb) infection are urgently required. By characterising natural protective immunity to Mtb infection we aimed to identify correlates of protection to guide vaccine development and other immune based therapies.
Introduction
Despite recent advances in diagnosis and treatment, tuberculosis (TB) remains is the leading infectious disease killer globally. Over 2 billion people are latently infected with Mycobacterium tuberculosis (Mtb) with 10 million new cases and 1.6 million deaths each year [1] . Strategies to prevent Mtb infection occurring in the first place are a high priority. A recent study showed that sustained QuantiFERON (QFT) conversion, which may best reflect the establishment of Mtb infection, was reduced by 45.4% with Bacillus Calmette-Guérin (BCG) re-vaccination of adolescents in a high-transmission setting [2] . An understanding of the underlying mechanism(s) for protection against infection are required in order to inform clinical development of new vaccine candidates and host-directed therapies.
The World Health Organization (WHO) strategy sets ambitious targets to 'End TB' through a multi-pronged attack, including a major escalation of research activities to identify novel approaches [3] . Therapeutics to prevent/clear Mtb infection is an alternative strategy that could turn the tide on the TB epidemic. Evidence for natural resistance to Mtb infection is best illustrated by the Lübeck disaster where ~20% of infants vaccinated with Mtb-contaminated BCG did not get infected [4] . In addition, studies of sailors in long-term confinement with a TB patient showed a surprisingly low level of infection [5] . It has also been shown that a proportion of highly Mtbexposed household contacts never acquire Mtb infection [6] . Importantly, longitudinal studies of such individuals confirm a much lower rate of progression to TB disease than those test positive for LTBI [7] suggesting that they are protected and not merely anergic to the antigens in diagnostic tests.
Several cell subsets have been proposed to control resistance to Mtb infection including macrophages, non-classical T cell subsets and B cells. Macrophage-dependent pathways that prevent bacterial uptake or rapidly clear Mtb before the development of an adaptive immune response define innate resisters while adaptive resisters are individuals in which T cell and B cell effector functions eliminate or restrict Mtb infections, either independently of IFN-γ production or through priming by non-protein antigens [8] . Further study is required to determine whether adaptive resisters have greater resistance to progression to active TB than individuals with traditionally defined LTBI [8] . Genome-wide association analysis has also identified loci that are associated with innate or adaptive resistance to Mtb infection [9] .
The aim of this study was to analyse transcriptomic and antibody signatures in Mtb infection converters and non-converters to identify subsets and pathways for rational development of novel interventions to enhance protection against Mtb infection.
Methods:

Study participants
Household contacts of TB index patients were recruited following written, informed consent by the participant or a parent/guardian if <18 years. They were screened to rule out active disease and infection status was determined using either Tuberculin skin test (TST) or QuantiFERON (QFT; Qiagen). TST was performed for participants recruited between 2002-2005 at baseline and 3 months using 2 tuberculin units (TU) of purified protein derivative (PPD) RT23 (SSI, Denmark) with a reading ≥ 10mm considered positive. QFT (Qiagen, Germany) was performed for participants recruited between 2016 and 2017 at baseline and 6 months according to the manufacturer instructions. Two participant groups were predefined: TST converters (those who were negative (0mm) at baseline and converted to positive (≥10mm) by 3 months) and TST non-converters (those who remained 0mm at both time-points). Similarly, analysis of QFT at baseline and 6 months defined QFT converters and non-converters. Whole blood RNA was stabilised in Paxgene RNA blood tubes and stored at -80 until analysis. Heparinised blood was centrifuged (600 gmax , 10 mins.), the plasma collected and stored at -20 o C until analysis. Differential blood counts were performed at baseline for all participants using a hematology analyser (Cell-Dyn, USA).
RNA-sequencing
RNA was extracted (Qiagen, Germany) and shipped to the Beijing Genome Institute (Hong Kong) and underwent Globin transcript depletion (GlobinClear, Life Technologies, UK). cDNA libraries were prepared using Illumina mRNA-Seq Sample Prep Kit and RNA-Seq was performed by Expression Analysis Inc., at 20 million 50bp paired-end reads, on Illumina HiSeq-2000 sequencers.
Read pairs were aligned to the hg19 human genome using gsnap24 which generated splice junction counts for each sample.
Mtb proteome arrays
IgG and IgA serum antibody reactivity to 4000 Mtb antigens was analysed using a full proteome microarray by Antigen Discovery Inc. (USA) as previously described [10, 11] . Briefly, proteome chips were probed with serum from TST converters and non-converters at baseline and 3 months.
Slides were first blocked for 30 min in protein array-blocking buffer before incubation with the primary antibody for 2h. Antibodies were detected with Cy3-conjugated secondary antibodies (Jackson ImmunoResearch) and scanned in a ScanArray 4000 laser confocal scanner (GSI Lumonics, Billerica, MA). Fluoresence intensities were quantified by using QUANTARRAY software (GSI Lumonics).
Statistics
Participant demographics:
Data were analysed a using Mann-Whitney U-test or Kruskal-Wallis test with Graph Pad Prism software v7.0 (Software MacKiev, USA).
RNA-sequencing
RNA Seq count data were processed using the edgeR package. For each batch, only genes with at least 5 counts per million in at least 3 samples were kept. For batch 1, a subset of samples was generated comprising only samples from HIV-individuals older than 17 years. Differential gene expression was analysed using glmLRT function from the edgeR package, which is a log-likelihood ratio test. Discordance analysis was performed using the disco package. Gene set enrichment analysis was performed using the tmod package. In addition, due to subset differences within each batch the ComBat function from the sva R package was used to remove the effect of sub-batches from logarithmized counts per million transformed data.
Antibody arrays:
For each antigen, the average intensity of all samples was determined. A Mann-Whitney U-test was performed for analysis between groups and adjusted for false discovery rates using the Benjamini-Hochberg test. The Area under the ROC curve (AUC) was used to determine differential reactivity for each antigen for both IgG and IgA.
Results:
Participant demographics
For metabolomics and antibody arrays, paired plasma samples from 40 converters and 38 nonconverters at baseline and 3 months were sent to Metabolon and Antigen Discovery for processing respectively. No difference in age or sex was seen between the groups but there was a significantly higher proportion of converters living in the same room as the index case (ie closest proximity; p=0.034) compared to non-converters ( Table 1) . For RNA-sequencing, analysis was performed on two batches based on TST (batch 1) or QFT (batch 2). For batch 1, 100 baseline RNA samples were sent to BGI for sequencing. Quality control prior to library preparation showed that only 46/100 samples were of optimal quality for sequencing (RIN≥7.0) presumably due to the long storage duration (up to 13 years). Of these 46 samples, 35 were TST non-converters and 11
were TST converters ( Table 1) . There was a similar proportion of males in both groups, but a significant difference in age (median[IQR] non-converters = 10[5-17] compared to 20[16-32] for the converters (p<0.001). There was no significant difference in proximity between the groups. For batch 2, samples from 16 QFT non-converters and 11 QFT converters were sequenced ( Table 1) .
No significant difference in age, sex or proximity was seen between the groups. Progression to active disease was assessed in all participants for a 24 month period with only 1 QFT converter progressing after 12 months and none of the non-converters progressing. No progressors were seen in the TST converter/non-converter group.
RNA-sequencing:
Several differentially expressed genes were observed between converters and non-converters at baseline. For the TST group, the most differentially expressed genes included TMEM56 (p=1.25E-08), RP11-364L4.1 (p=4.52E-08), LCN2 (p=1.81E-07), CLIC2 (p=3.50E-07) and WASHC3 (p=3.54E-07) ( Table 2) . For the QFT group, the most differentially expressed genes included RPS9 (p=3.14E-10), MDM4 (p=6.09E-07), HSFX3 (7.6E-07) and IGF1R (p=5.25E-06) all of which were upregulated in the converters ( Table 3) . A full description of differentially expressed genes is shown in supplementary table 1. Due to the significant difference in age between the TST converters and non-converters, we also performed filtered analysis of adults only ( Table 4) .
Interestingly in this group the top genes included several coding for immune-regulatory functions including CXCL10 (p=3.10E-05), HLA-DQB1 (p=8.53E-04) and CD22 (p=1.58E-03). However, significance was lost after adjusting for FDR, most likely due to low numbers in both groups.
CXCL10 (IP-10) showed a significant down-regulation in the non-converters while CD22 (inhibitory receptor for B cell receptor signalling; member of Ig superfamily) showed an up-regulation.
Interestingly, HLA-DQB1 was highly upregulated in the TST non-converters (logFC = -5.6)
suggesting this gene may be involved in protection against Mtb infection. Next we performed gene set enrichment analysis using the Tmod package in R. In the total TST-defined group, there was a strong enrichment in B-cell related genes in the TST non-converters ( Fig. 1A) , which was still evident in the filtered subgroup ( Fig. 1B) . TST converters had significant enrichment for TLR8-BAFF related genes and monocytes ( Fig. 1A) although this was lost when filtering was performed.
The responses in the QFT non-converters were dominated by an interferon-Type I/anti-viral gene signature (Fig. 1C) . It is important to note there were no significant differences in white blood cell counts between converters and non-converters (data not shown). However, due to the differences in proximity (ie exposure) of each participants, we next assessed how this affected gene expression profiles ( Fig. 2) . Interestingly, in those with the lowest exposure, gene signatures were generally within the innate immune cells with enrichment of neutrophils, monocytes and TLR pathways. The B cell signature was only evident in those with the highest exposure to the index TB case (Fig. 2) .
This suggests that B cells are involved in the early protective immune response to Mtb infection.
Mtb antibody arrays:
Analysis of both IgG and IgA reactivity to the Mtb proteome showed similar findings with extensive differences in reactivity evident (supplementary Table 2 ). There was a significant exposure gradient effect with the AUC increasing as proximity to the index case increased (Fig. 3) . For example, with IgG reactivity to Rv2131c, Rv0363c and Rv3223c the AUC was 0.73, 0.83 and 0.96 respectively and with IgA reactivity to Rv0134 at the closest proximity, the AUC was 1.00. This indicates that antibody reactivity can be used to discriminate between TST converters and nonconverters. Surprisingly, however, the majority of reactivity was higher in the converters (Fig. 3   (red) ) suggesting that the enrichment of B cell genes we saw in the non-converters was not primarily due to enhanced antibody production. However, when the most reactive antigens were analysed, non-converters showed higher responses to Rv0831c (fold increase (fi) 1.93), Rv3038c
(fi 2.32), Rv2946c (fi 2.09), Rv3604c (fi 2.53), Rv0726c (fi 1.93) and Rv2396 (fi 2.00) ( Fig. 4) .
We next analysed reactivity to ESAT-6 specific antigens since this is a dominant secretory antigen from Mtb. Only individuals in the closest proximity to the index case showed any differential antibody reactivity to ESAT-6 antigens with the most significant being IgG reactivity to Rv3875 (p=0.0008). IgA reactivity to Rv3872 (p=0.025) and Rv3871 (p=0.030) were both increased in converters compared to non-converters at baseline (supplementary Table 2 ).
Discussion:
We have characterised host transcriptomic and antibody responses to Mtb in TST non-converters and converters prior to any signs of infection as determined by current methods. We have previously shown higher levels of soluble IL-17 in non-converters at baseline [12] suggesting they have encountered Mtb and mounted an immune response and are not simply anergic to antigens in the current tests nor is Mtb blocked by physiological barriers. In this study we saw a distinct B It was interesting to see the distinct gene signatures present when infection was defined by QFT rather than TST. Whilst different mechanisms will be inevitable since TST is based on a delayed type hypersensitivity reaction of 48-72 hours while QFT is based on overnight in vitro stimulation, the fact these signatures are upregulated in the uninfected groups, suggests they are likely to play a role in resistance. Increased production of Type I interferons (IFNα/β) as part of the anti-viral response inhibits the downstream effects of Type II interferon (IFN-γ) responses known to be critical for Mtb control [20] . Thus it was surprising to see an increase in these genes in the QFT non-converters. However, it has previously been shown that in the absence of a response to IFN-γ, type I IFNs play a non-redundant protective role against tuberculosis in mice [21] and suggest type I IFN can limit the number of target cells that Mtb can infect in the lungs while IFN-γ enhances their ability to restrict bacterial growth [21] . It has also been shown in experimental models that Type I IFN may play a protective role in the context of BCG-induced immunity and could be targeted to improve preventive vaccination against tuberculosis [22] .
The enrichment of B cell genes was unexpected so we decided to analyse IgG and IgA plasma antibody reactivity to all 4000 Mtb proteins from these same individuals. TST converters had significantly higher levels of both IgG and IgA antibodies to multiple Mtb antigens at baseline, which allowed excellent discrimination between converters and non-converters. This was particularly evident when proximity was accounted for: exposed contacts in closest proximity to the index case who later converted their TST had higher antibody levels at baseline. This suggests 
